Promega Secures SBTi Validation for 2030 Emissions Reduction Targets…

Event summary

Promega received SBTi validation for its near-term emissions reduction targets, covering Scope 1, 2, and 3 emissions through 2030.
Targets include a 47% reduction in Scope 1 and 2 emissions, a 42% reduction in Scope 3 emissions, and 67% of suppliers committing to SBTi by 2030.
Promega has already achieved 100% renewable electricity across its global operations.
The validation adds third-party accountability for customer procurement teams and sustainability officers.

The big picture

Promega's SBTi validation aligns with the growing trend of biotechnology and pharmaceutical companies adopting science-based emissions reduction targets. This move is strategically significant as procurement teams increasingly prioritize suppliers with third-party validated sustainability goals. The validation not only enhances Promega's credibility but also positions it favorably in a market where sustainability is becoming a key differentiator.

What we're watching

Execution Risk: How Promega will manage the operational challenges of reducing Scope 3 emissions, particularly in capital goods and business travel.
Supplier Engagement: Whether Promega can successfully engage 67% of its suppliers by spend to commit to SBTi or publish SBTi-aligned reduction targets by 2030.
Industry Benchmarking: The pace at which other biotechnology and pharmaceutical companies adopt similar SBTi-validated targets, setting new industry standards.